It is important to note that studies of NSCLC derived from patients receiving several cycles of platinum-based therapy found downregulation of NKG2D ligands and upregulation of program death receptor ligand-1 (PD-L1), supporting the attenuation of NK and CD8+ T cell-mediated tumor cell death [24]. Here, CD8A is linked to neoplasm.